In Phase 1 portion of trial, WVE-007 improved body composition by inducing fat loss, including harmful visceral fat, while maintaining muscle; data continue to support once or twice-yearly dosing

Phase 2a portion in individuals with higher BMI and body fat, with and without type 2 diabetes, includes multiple assessments to inform further development of WVE-007 in obesity as well as MASH, type 2 diabetes, and cardiovascular disease

Wave is on track to initiate additional Phase 2 trials in 2H 2026 evaluating WVE-007 in combination with incretins and as post-incretin maintenance

CAMBRIDGE, Mass., June 24, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced it has initiated the Phase 2a multidose portion of the INLIGHT™ trial, a placebo-controlled (3:1) study evaluating WVE-007, an investigational GalNAc-siRNA, as monotherapy in individuals living with obesity with high BMI (35-50 kg/m2) and comorbidities.

The INLIGHT trial also includes an ongoing Phase 1 single dose portion investigating WVE-007 in otherwise healthy individuals living with overweight or obesity, with an average BMI of 32 kg/m2. In this portion of the trial, at six months of follow-up, a single 240 mg dose of WVE-007 continued to drive clinically meaningful reductions in visceral fat (-14%; p<0.05), total fat (-5%), and waist circumference (-3%). WVE-007 continues to be generally safe and well tolerated up to 600 mg and data support the potential for once or twice-yearly dosing. The Phase 2a portion of the INLIGHT trial is expected to demonstrate further body composition improvements, including greater fat loss with preserved muscle, weight loss, and improved biomarkers of cardiometabolic health.